Recent advance of next-generation sequencing in patients with lung cancer

Qiu, Tianyu; Zhi, Xinxin; Ren, Shengxiang

doi:10.1080/14737159.2023.2260755

Cited by 1 publication

(2 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To increase LB sensitivity, blood samples could be repeated at different times or other biological fluids (e.g., saliva, urine, sputum) could be analysed as an alternative or in combination with plasma ( Lino et al, 2023 ; Xin et al, 2023 ). On the other hand, LB does not seem to be indicated for early-stage tumours, showing a high rate of FN results, possibly due to the scarcity/lack of tDNA shed into circulation, or to the technical limits of current detection methods ( Qiu et al, 2023 ).…”

Section: Discussionmentioning

confidence: 99%

“…NGS also allows the comprehension of tumour genetic features and provides crucial information on tumour microenvironment and immune response, that might drive the response to immunotherapy. (Qiu et al, 2023). PCR-based techniques are characterized by a short turnaround time and easy interpretation of results, but allow the detection of only one alteration at a time.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Liquid biopsy in non-small cell lung cancer: a meta-analysis of state-of-the-art and future perspectives

Franzi,

Seresini,

Borella

et al. 2023

Front. Genet.

View full text Add to dashboard Cite

Introduction: To date, tissue biopsy represents the gold standard for characterizing non-small-cell lung cancer (NSCLC), however, the complex architecture of the disease has introduced the need for new investigative approaches, such as liquid biopsy. Indeed, DNA analyzed in liquid biopsy is much more representative of tumour heterogeneity.Materials and methods: We performed a meta-analysis of 17 selected papers, to attest to the diagnostic performance of liquid biopsy in identifying EGFR mutations in NSCLC.Results: In the overall studies, we found a sensitivity of 0.59, specificity of 0.96 and diagnostic odds ratio of 24,69. Since we noticed a high heterogeneity among different papers, we also performed the meta-analysis in separate subsets of papers, divided by 1) stage of disease, 2) experimental design and 3) method of mutation detection. Liquid biopsy has the highest sensitivity/specificity in high-stage tumours, and prospective studies are more reliable than retrospective ones in terms of sensitivity and specificity, both NGS and PCR-based techniques can be used to detect tumour DNA in liquid biopsy.Discussion: Overall, liquid biopsy has the potential to help the management of NSCLC, but at present the non-homogeneous literature data, lack of optimal detection methods, together with relatively high costs make its applicability in routine diagnostics still challenging.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%